Skip to main content

Advertisement

Table 1 Participant Characteristics (Concept Elicitation)

From: Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Characteristic US UK Germany Total Samplea
N 11 14 7 32
Mean Age (years) (SD) 56.91 (11.4) 59.57 (14.0) 67.43 (5.4) 60.38 (12.0)
Gender
 Female 7 (63.6%) 6 (42.9%) 3 (42.9%) 16 (50.0%)
 Male 4 (36.4%) 8 (57.1%) 4 (57.1) 16 (50.0%)
Ethnic/Racial Background (n, %)
 White 4 (36.4%) 12 (85.7%) 7 (100.0%) 23 (71.9%)
 Mixed 1 (9.1%) 0 (0.0%) 0 (0.0%) 1 (3.1%)
 Asian 1 (9.1%) 0 (0.0%) 0 (0.0%) 1 (3.1%)
 Black 4 (36.4%) 2 (14.3%) 0 (0.0%) 6 (18.8%)
 Otherb 1 (9.1%) 0 (0.0%) 0 (0.0%) 1 (3.1%)
Marital Status (n, %)
 Single 1 (9.1%) 4 (28.6%) 0 (0.0%) 5 (15.6%)
 Married/Living with partner 6 (54.5%) 7 (50.0%) 4 (57.1%) 17 (53.1%)
 Otherc 4 (36.4%) 3 (21.4%) 3 (42.9%) 10 (31.3%)
Employment Status (n, %)d
 Full-time work 5 (45.5%) 2 (14.3%) 1 (14.3%) 8 (25.0%)
 Part-time work 1 (9.1%) 2 (14.3%) 0 (0.0%) 3 (9.4%)
 Othere 5 (45.5%) 10 (71.4%) 6 (85.7%) 21 (65.6%)
Education Level (n, %)
 University degree 5 (45.5%) 3 (21.4%) 2 (28.6%) 10 (31.3%)
 No University degree 6 (54.5%) 11 (78.6%) 5 (71.4%) 22 (68.7%)
Interview Type
 In-Person (n) 1 (9.1%) 14 (100.0%) 1 (14.3%) 16 (50.0%)
 Telephone (n) 10 (90.9%) 0 (0.0%) 6 (85.7%) 16 (50.0%)
Medication History
 Current GLP-1 7 (63.6%) 11 (78.6%) 7 (100.0%) 25 (78.1%)
 Discontinued GLP-1 0 (0.0%) 2 (14.3%) 0 (0.0%) 2 (6.3%)
 Current GLP-1 and Insulin 4 (36.4%) 1 (7.1%) 0 (0.0%) 5 (15.6%)
Current GLP-1 RAs
 Liraglutide 3 (27.3%) 3 (21.4%) 4 (57.1%) 10 (31.3%)
 Exenatide twice daily 0 (0.0%) 4 (28.6%) 1 (14.3%) 5 (15.6%)
 Exenatide extended release tray 1 (9.1%) 1 (7.1%) 2 (28.6%) 4 (12.5%)
 Lixisenatide 0 (0.0%) 4 (28.6%) 0 (0.0%) 4 (12.5%)
 Exenatide extended release pen 3 (27.3%) 0 (0.0%) 0 (0.0%) 3 (9.4%)
 Dulaglutide 2 (18.2%) 0 (0.0%) 0 (0.0%) 2 (6.3%)
 Albiglutide 2 (18.2%) 0 (0.0%) 0 (0.0%) 2 (6.3%)
Discontinued GLP-1 RAsf
 Liraglutide 1 (9.1%) 1 (7.1%) 0 (0.0%) 2 (6.3%)
 Exenatide extended release pen 1 (9.1%) 1 (7.1%) 0 (0.0%) 2 (6.3%)
  1. aThis table includes data for the 32 participants who provided proof of medication, were eligible, and completed a satisfactory interview according to the interview guide. Two additional participants were enrolled in the study but excluded from the analysis sample because of deviations from the interview guide
  2. bOther ethnic/racial background includes: Hispanic (total: n = 1; US: n = 1)
  3. cOther marital status includes: Divorced (total: n = 7; US: n = 4; Germany: n = 3); Separated (total: n = 2; UK: n = 2), Widowed (total: n = 1; UK: n = 1)
  4. dPercentages for employment status in the US sum to 100.1% due to rounding
  5. eOther employment status includes: US: Retired (n = 3), Retired and disabled (n = 2); UK: Retired (n = 9), Homemaker (n = 1); Germany: Retired (n = 5), Retired and disabled (n = 1)
  6. fGLP-1 RAs discontinued within the past 6 months. No patients reported discontinuing any GLP-1 RAs other than liraglutide and exenatide once weekly